- Home
- NEXT vs CNTA Comparison
NEXT vs CNTA Comparison
Compare NEXT & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEXT
- CNTA
- Stock Information
- Founded
- NEXT 2010
- CNTA 2020
- Country
- NEXT United States
- CNTA United Kingdom
- Employees
- NEXT N/A
- CNTA N/A
- Industry
- NEXT Oil & Gas Production
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- NEXT Energy
- CNTA Health Care
- Exchange
- NEXT Nasdaq
- CNTA Nasdaq
- Market Cap
- NEXT 1.9B
- CNTA 1.8B
- IPO Year
- NEXT N/A
- CNTA 2021
- Fundamental
- Price
- NEXT $7.67
- CNTA $12.30
- Analyst Decision
- NEXT Hold
- CNTA Strong Buy
- Analyst Count
- NEXT 1
- CNTA 10
- Target Price
- NEXT $9.00
- CNTA $26.11
- AVG Volume (30 Days)
- NEXT 1.4M
- CNTA 617.5K
- Earning Date
- NEXT 05-06-2025
- CNTA 05-20-2025
- Dividend Yield
- NEXT N/A
- CNTA N/A
- EPS Growth
- NEXT N/A
- CNTA N/A
- EPS
- NEXT N/A
- CNTA N/A
- Revenue
- NEXT N/A
- CNTA N/A
- Revenue This Year
- NEXT N/A
- CNTA N/A
- Revenue Next Year
- NEXT N/A
- CNTA N/A
- P/E Ratio
- NEXT N/A
- CNTA N/A
- Revenue Growth
- NEXT N/A
- CNTA N/A
- 52 Week Low
- NEXT $4.27
- CNTA $7.75
- 52 Week High
- NEXT $9.71
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- NEXT 52.96
- CNTA 40.97
- Support Level
- NEXT $7.17
- CNTA $11.88
- Resistance Level
- NEXT $7.78
- CNTA $14.39
- Average True Range (ATR)
- NEXT 0.34
- CNTA 0.79
- MACD
- NEXT 0.03
- CNTA -0.00
- Stochastic Oscillator
- NEXT 77.44
- CNTA 18.68
About NEXT NextDecade Corporation
NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas and sale of LNG and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.